6 Results

People

  1. Hellmann
    Hellmann
  2. Riely
    Riely
  3. Arbour
    Arbour
  4. Friedman
    Friedman
  5. Girshman
    Girshman
  6. Hultcrantz
    Hultcrantz
  7. Iqbal
    Iqbal
  8. Kris
    Kris
  9. Lu
    Lu
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (3)
  4. Hematologic Malignancies, Division of (2)
  5. Weinberg Fellows (2)
  6. Biostatistics Service (1)
  7. Body Imaging Service (1)
  8. Center for Hematologic Malignancies (1)
  9. Epidemiology and Biostatistics (1)
  10. GDMT, Medicine (1)
  1. "clinical activity"
Formats
  1. Journal Article (4)
  2. Book Section (1)
  3. Review (1)
Groups
  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (3)
  4. Hematologic Malignancies, Division of (2)
  5. Weinberg Fellows (2)
  6. Biostatistics Service (1)

More Groups

People
  1. Gregory Riely (2)
  2. Matthew Hellmann (2)
  3. Adam Schoenfeld (1)
  4. Afsheen Iqbal (1)
  5. Claire Friedman (1)
  6. Dajun Lu (1)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2019 (3)
  4. 2018 (1)
Publications
  1. Annals of Oncology (3)
  2. Cancer (1)
  3. Frontiers in Pharmacology (1)
  4. Oncology Clinical Trials: Successful Design, Conduct, and Analysis. 2nd ed (1)
Publishers
  1. Oxford University Press (3)
  2. Demos Medical Publications (1)
  3. Frontiers Media S.A. (1)
  4. Wiley Blackwell (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The outcast of medicine: Metals in medicine--From traditional mineral medicine to metallodrugs
    Review

    Bai, D.; Nowak, M.; Lu, D.; Wang, Q.; Fitzgerald, M.; Zhang, H.; Macdonald, R.; Xu, Z.; Luo, L.
    Frontiers in Pharmacology (2025)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001
    Journal Article

    Shaw, A. T.; Riely, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Solomon, B. J.; Varella-Garcia, M.; Iafrate, A. J.; Shapiro, G. I.; Usari, T.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
    Journal Article

    Hellmann, M. D.; Kim, T. W.; Lee, C. B.; Goh, B. C.; Miller, W. H. Jr; Oh, D. Y.; Jamal, R.; Chee, C. E.; Chow, L. Q. M.; Gainor, J. F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    Journal Article

    Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Special considerations in immunotherapy trials
    Book Section

    Friedman, C. F.; Panageas, K. S.; Wolchok, J. D.
    In Kelly, W. K.; Halabi, S. (Eds.) Oncology Clinical Trials: Successful Design, Conduct, and Analysis. 2nd ed (2018)

    Fulltext@MSK | Save